{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045361","form_type":"8-K","ticker":"USAQ","cik":"0000856984","company_name":"QHSLab, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.161659+00:00","generated_at":"2026-05-30T00:41:54.381228+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"QHSLab Q3 revenue up 62% to $544K, net income $49.8K, gross margin 67.1%","bullets":["Revenue $544,285 (+62% YoY); gross margin 67.1% (up from 56.3%). Net income $49,765 vs ($82,000) loss in Q3 2023.","ISP (digital health) segment revenue up 126% in Q3 to ~$162K; YTD growth 143% to ~$450K.","Allergy kit sales +48% YoY to ~$220K. Surpassed 100,000 completed digital assessments.","Debt reduction of >$100K from operating cash flow; R&D investment up to $187K YTD.","Secured ~$300K grant for allergic rhinitis digital health research."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045361","json":"https://secwatch.observer/filing/0001493152-24-045361.json","markdown":"https://secwatch.observer/filing/0001493152-24-045361.md","text":"https://secwatch.observer/filing/0001493152-24-045361.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/856984/000149315224045361/0001493152-24-045361-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/856984/000149315224045361/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:41:54.381228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}